Haemonetics Corporation Common Stock (HAE)
67.16
0.00 (0.00%)
Haemonetics Corporation is a global healthcare company that specializes in providing innovative blood management solutions
The company develops and manufactures a range of systems and products designed to optimize the collection, processing, and transfusion of blood and its components. Haemonetics focuses on enhancing blood safety and efficiency within healthcare settings, offering technologies that support blood donation and transfusion processes, as well as promoting the overall health of patients through effective blood management practices. Their commitment to improving patient outcomes and supporting healthcare providers makes them a key player in the field of healthcare technology.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (NASDAQSTAA) and the best and worst performers in the medical devices & supplies - specialty industry.
Via StockStory · February 28, 2025

Eyecare company Bausch + Lomb (NYSEBLCO)
will be announcing earnings results tomorrow morning. Here’s what to expect.
Via StockStory · February 18, 2025

Medical technology company Inspire Medical Systems (NYSEINSP)
will be reporting results tomorrow after market close. Here’s what you need to know.
Via StockStory · February 9, 2025

HAEMONETICS CORP/MASS is a hidden gem, featuring undervaluation and robust fundamentals. NYSE:HAE showcases decent financial health and profitability, coupled with an attractive price.
Via Chartmill · February 7, 2025

Via Benzinga · February 7, 2025

Blood products company Haemonetics (NYSEHAE). fell short of the market’s revenue expectations in Q4 CY2024 as sales rose 3.7% year on year to $348.5 million. Its non-GAAP profit of $1.19 per share was 1.7% above analysts’ consensus estimates.
Via StockStory · February 6, 2025

Blood products company Haemonetics (NYSEHAE).
will be announcing earnings results tomorrow before the bell. Here’s what to expect.
Via StockStory · February 5, 2025

For those who appreciate growth without the sticker shock, HAEMONETICS CORP/MASS (NYSEHAE) is worth considering.
Via Chartmill · December 13, 2024

Via Benzinga · December 6, 2024

Via Benzinga · November 8, 2024

While growth is established for NYSE:HAE, the stock's valuation remains reasonable.
Via Chartmill · October 31, 2024

HAEMONETICS CORP/MASS (NYSEHAE), a growth stock which is not overvalued.
Via Chartmill · October 10, 2024

In the world of growth stocks, NYSE:HAE shines as a value proposition.
Via Chartmill · November 21, 2024

Investors should take note ofHAEMONETICS CORP/MASS (NYSEHAE), a growth stock that remains attractively priced.
Via Chartmill · September 18, 2024

Looking for growth without the hefty price tag? Consider NYSE:HAE.
Via Chartmill · August 28, 2024

Via Benzinga · August 16, 2024

Investors seeking growth at a reasonable cost should explore HAEMONETICS CORP/MASS (NYSEHAE).
Via Chartmill · August 6, 2024

NYSE:HAE is not too expensive for the growth it is showing.
Via Chartmill · July 16, 2024

HAEMONETICS CORP/MASS (NYSEHAE) stands out as a growth opportunity that won't break the bank.
Via Chartmill · June 25, 2024